Your browser doesn't support javascript.

BVS IEC

Instituto Evandro Chagas

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

Carneiro Neto, José Abraão; Bittencourt, Valéria Gusmão; de Oliveira, Cassius; Andrade, Rosana; de Carvalho, Edgar Marcelino.
Rev. Soc. Bras. Med. Trop; 47(4): 528-532, Jul-Aug/2014. tab, graf
Artigo em Inglês | LILACS | ID: lil-722305
Urinary symptoms occur in 19% of human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients who do not fulfill criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP patients. Few studies have evaluated therapies for overactive bladder (OAB) caused by HTLV-1 infection. This case report describes the effect of onabotulinum toxin A on the urinary manifestations of three patients with HAM/TSP and OAB symptoms. The patients were intravesically administered 200 units of Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS) reduced significantly. These data indicate that Botox® should be a treatment option for OAB associated with HTLV-1 infection.
Biblioteca responsável: BR1.1